Dr. George J. Bosl will receive the ASCO Distinguished Achievement Award for his pioneering work in research and patient care dealing with the management of testicular cancer and other genitourinary cancers.
Ovarian function suppression has the potential to affect fertility, however providers should be aware of the role of adjuvant therapy and other interventions in helping patients maintain bone density and reduce fracture risk.
ASCO published guidelines and endorsements addressing myriad aspects of prostate cancer care, including radiotherapy in men after prostatectomy, hormone therapy and chemotherapy, and survivorship care.
Learn more about the inaugural year of the Maintenance of Certification (MOC) Self-Assessment Activity at the 2015 Genitourinary Cancer Symposium through an interview with participant Dr. Elizabeth Guancial.
Arguments for treating men with castration-resistant prostate cancer early or late were provided based on data from CHAARTED and GETUG-AFU 15. In addition, the use and sequencing of Ra 223 were also provided based on analyses from ALSYMPCA and datasets from clinical practice.
Treatment with the Wee1 inhibitor AZD1775 plus carboplatin showed encouraging antitumor activity in patients with p53-mutated ovarian cancer that is refractory or resistant to standard first-line therapy.
The randomized phase III TOAD trial investigated whether immediate intervention with androgen deprivation therapy would improve overall survival compared with delayed androgen deprivation therapy in patients with prostate cancer.
The Education Session “Managing Ovarian Cancer in the Older Woman: How to Best Select and Sequence Surgery and Chemotherapy for Optimal Outcome” addresses the challenges clinicians face in treating older women with ovarian cancer.
The addition of docetaxel chemotherapy to standard therapies for men with either high-risk, localized prostate cancer (RTOG 0521, #LBA5002) or hormone-naive, advanced prostate cancer (STAMPEDE, #5001) resulted in significant OS improvements.
The addition of bevacizumab to everolimus is associated with a significant improvement in efficacy but a high rate of toxicity in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (pNETs), according to results of the randomized, phase II CALGB 80701 trial.
One year of neratinib improved the rate of invasive disease-free survival compared to placebo in patients with HER2-positive early stage breast cancer who had undergone prior adjuvant therapy with chemotherapy and trastuzumab, according to results of a randomized phase III trial.